Education
About Us
Working with TipRanks
Follow Us
Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
ILA Stock Chart & Stats
AU$0.44
<AU$0.01(1.74%)
At close: 4:00 PM EST
AU$0.44
<AU$0.01(1.74%)
Day’s Range― - ―
52-Week RangeAU$0.12 - AU$0.63
Previous CloseN/A
Volume208.69K
Average Volume (3M)781.24K
Market Cap
AU$123.80M
Enterprise ValueAU$100.66M
Total Cash (Recent Filing)AU$6.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.71
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding294,766,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageZero reported debt gives Island Pharmaceuticals durable financial flexibility to fund R&D and clinical programs without immediate interest burden. Over a 2-6 month horizon, low leverage reduces solvency risk, eases covenants concerns, and improves optionality for strategic financing or partnerships.
Material Equity CushionA sizeable equity base provides a buffer to absorb operating losses common in early-stage biotech. This cushion lengthens runway before urgent external financing, supports ongoing trial spending and helps preserve negotiating power in potential licensing or partner deals over the medium term.
Focused Antiviral R&DA clear strategic focus on antiviral therapeutics aligns with persistent global healthcare need and can concentrate R&D expertise and resources. Over months, this specialization supports credible pipeline prioritization, partner interest and targeted capital allocation toward high-impact clinical milestones.
Bears Say
Persistent Cash BurnSustained negative operating cash flow signals ongoing cash burn to support operations and trials. Even with modest year-over-year improvement, continued outflows create dependency on external financing, raising dilution risk and potentially forcing non-strategic funding choices that can impair long-term value creation.
Sharp Revenue DeclineA 70% revenue decline highlights weak commercial traction or lumpy milestone timing, reducing internal funding capacity. Over a medium horizon this volatility undermines predictable cash generation, complicates budgeting for clinical programs and increases the probability of near-term capital raises.
Sustained Losses And Negative ROELarge recurring net losses and negative returns on equity indicate poor capital efficiency and that shareholder capital is being consumed. Persisting deficits erode equity despite its current size and elevate the likelihood of dilution, constraining management's ability to fund growth without external support.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.12 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$123.80M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 164 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 19, 2026. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.014.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.01.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 294,766,700 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.019 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went up 1.351%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$76.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-90.37%
Trailing 12-Months
Asset Growth
192.19%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---